Silver Book Fact

The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.

Romley J, Sanchez Y, Penrod J, Goldman D, et al. Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs. Health Affairs. 2012; 31(4): 683-690. https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2011.1301

Reference

Title
Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2012
Authors
Romley J, Sanchez Y, Penrod J, Goldman D, et al.
Volume & Issue
Volume 31, Issue 4
Pages
683-690
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The 5-year survival rate for cancer has gone up 40 percent in the last 40 years.  
  • A modest 1% reduction in cancer mortality would be worth close to $500 billion. A cure for cancer (if one is feasible) would be worth around $50 trillion.  
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in development is designed to induce a powerful immune response to melanoma.  
  • Five-year Relative Survival (%) during Three Time Periods by Cancer Site  
  • Between 1990/1991 and 2008, the overall cancer mortality rates decreased by 22.9 percent in men and 15.3 percent in women—around 1,024,400 deaths avoided—primarily due to reductions in tobacco use among…